Matches in SemOpenAlex for { <https://semopenalex.org/work/W2113455935> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2113455935 endingPage "7" @default.
- W2113455935 startingPage "5874" @default.
- W2113455935 abstract "On the basis of its high degree of cytotoxicity against fresh human ovarian cancers and its relative lack of vesicant activity, mitoxantrone administered by the i.p. route was studied in a Phase I and pharmacokinetic trial. Thirty-three patients with good performance status and diagnoses of metastatic or recurrent ovarian (31 patients) and colon (two patients) cancers were treated with 12- to 38-mg/m2 doses, administered by the i.p. route every 4 wk for up to ten treatment courses. Mitoxantrone doses were escalated at 2- to 3-mg/m2 increments in groups of three to 11 patients. Thirty-eight mg/m2 (by i.p. dwell without removal) were considered the maximally tolerated dose in that, of eight treated patients, four experienced severe leukopenia and six experienced severe abdominal pain. Response to i.p. mitoxantrone was evaluable in 17 patients. None of seven patients with clinically measurable intraabdominal or pelvic tumor masses responded; however, in three (50%) of six patients with nonmeasurable disease, there was normalization of previously elevated serum CA-125 concentrations for 3, 17, and 24 mo. Additionally, two (50%) of four patients who underwent third-look laparotomies were found to have greater than 75% reductions in i.p. tumor masses with response lasting 24 and 25 mo. At 38 mg/m2, mitoxantrone was associated with a mean concentration.time product of 100 micrograms.h/ml in the i.p. space and of 0.071 micrograms.h/ml in plasma, yielding an i.p./plasma area under the curve ratio of 1408. We conclude that chemical peritonitis is the dose-limiting toxicity of i.p. administered mitoxantrone and that a dose of 23 mg/m2 every 3 to 4 wk should be used in future Phase II trials in ovarian cancer patients with minimal residual intraabdominal and pelvic disease following second-look laparotomy." @default.
- W2113455935 created "2016-06-24" @default.
- W2113455935 creator A5000227769 @default.
- W2113455935 creator A5016715621 @default.
- W2113455935 creator A5023044742 @default.
- W2113455935 creator A5029541691 @default.
- W2113455935 creator A5043099596 @default.
- W2113455935 creator A5050665980 @default.
- W2113455935 creator A5077941573 @default.
- W2113455935 creator A5082198836 @default.
- W2113455935 date "1988-10-15" @default.
- W2113455935 modified "2023-10-16" @default.
- W2113455935 title "Phase I clinical and pharmacokinetic study of mitoxantrone given to patients by intraperitoneal administration." @default.
- W2113455935 cites W1857558272 @default.
- W2113455935 cites W2020378287 @default.
- W2113455935 cites W2036183214 @default.
- W2113455935 cites W2042849799 @default.
- W2113455935 cites W2049033959 @default.
- W2113455935 cites W2057868260 @default.
- W2113455935 cites W2069175404 @default.
- W2113455935 cites W2171177278 @default.
- W2113455935 cites W2411596188 @default.
- W2113455935 cites W2416872489 @default.
- W2113455935 cites W2766663297 @default.
- W2113455935 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/3167842" @default.
- W2113455935 hasPublicationYear "1988" @default.
- W2113455935 type Work @default.
- W2113455935 sameAs 2113455935 @default.
- W2113455935 citedByCount "24" @default.
- W2113455935 countsByYear W21134559352021 @default.
- W2113455935 crossrefType "journal-article" @default.
- W2113455935 hasAuthorship W2113455935A5000227769 @default.
- W2113455935 hasAuthorship W2113455935A5016715621 @default.
- W2113455935 hasAuthorship W2113455935A5023044742 @default.
- W2113455935 hasAuthorship W2113455935A5029541691 @default.
- W2113455935 hasAuthorship W2113455935A5043099596 @default.
- W2113455935 hasAuthorship W2113455935A5050665980 @default.
- W2113455935 hasAuthorship W2113455935A5077941573 @default.
- W2113455935 hasAuthorship W2113455935A5082198836 @default.
- W2113455935 hasConcept C112705442 @default.
- W2113455935 hasConcept C126322002 @default.
- W2113455935 hasConcept C141071460 @default.
- W2113455935 hasConcept C2776694085 @default.
- W2113455935 hasConcept C2780873365 @default.
- W2113455935 hasConcept C2780923524 @default.
- W2113455935 hasConcept C31760486 @default.
- W2113455935 hasConcept C71924100 @default.
- W2113455935 hasConcept C90924648 @default.
- W2113455935 hasConceptScore W2113455935C112705442 @default.
- W2113455935 hasConceptScore W2113455935C126322002 @default.
- W2113455935 hasConceptScore W2113455935C141071460 @default.
- W2113455935 hasConceptScore W2113455935C2776694085 @default.
- W2113455935 hasConceptScore W2113455935C2780873365 @default.
- W2113455935 hasConceptScore W2113455935C2780923524 @default.
- W2113455935 hasConceptScore W2113455935C31760486 @default.
- W2113455935 hasConceptScore W2113455935C71924100 @default.
- W2113455935 hasConceptScore W2113455935C90924648 @default.
- W2113455935 hasIssue "20" @default.
- W2113455935 hasLocation W21134559351 @default.
- W2113455935 hasOpenAccess W2113455935 @default.
- W2113455935 hasPrimaryLocation W21134559351 @default.
- W2113455935 hasRelatedWork W1984192199 @default.
- W2113455935 hasRelatedWork W2042849799 @default.
- W2113455935 hasRelatedWork W2057337825 @default.
- W2113455935 hasRelatedWork W2067738925 @default.
- W2113455935 hasRelatedWork W2069681280 @default.
- W2113455935 hasRelatedWork W2089129023 @default.
- W2113455935 hasRelatedWork W2411586928 @default.
- W2113455935 hasRelatedWork W2412068487 @default.
- W2113455935 hasRelatedWork W2412893885 @default.
- W2113455935 hasRelatedWork W2884559333 @default.
- W2113455935 hasVolume "48" @default.
- W2113455935 isParatext "false" @default.
- W2113455935 isRetracted "false" @default.
- W2113455935 magId "2113455935" @default.
- W2113455935 workType "article" @default.